| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| nivolumab and ipilimumab | 0.43 | 0.9 | 8650 | 7 | 24 |
| nivolumab | 0.93 | 0.7 | 1966 | 9 | 9 |
| and | 1.48 | 0.7 | 6053 | 30 | 3 |
| ipilimumab | 1.57 | 0.7 | 5732 | 43 | 10 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| nivolumab and ipilimumab | 0.65 | 0.1 | 9990 | 3 |
| nivolumab and ipilimumab therapy | 0.55 | 0.2 | 9303 | 9 |
| nivolumab and ipilimumab lung cancer | 1.53 | 0.5 | 3316 | 12 |
| nivolumab and ipilimumab mesothelioma | 0.57 | 0.2 | 5447 | 31 |
| nivolumab and ipilimumab melanoma | 1.11 | 0.6 | 2676 | 13 |
| nivolumab and ipilimumab combination therapy | 1.42 | 0.8 | 2110 | 94 |
| nivolumab and ipilimumab side effects | 1.3 | 0.7 | 4639 | 90 |
| nivolumab and ipilimumab trial | 1.99 | 0.6 | 3281 | 17 |
| nivolumab and ipilimumab renal cell carcinoma | 0.93 | 1 | 7535 | 29 |
| nivolumab and ipilimumab sarcoma | 0.65 | 0.9 | 369 | 54 |
| nivolumab and ipilimumab success stories | 1.61 | 0.7 | 6026 | 19 |
| nivolumab and ipilimumab cost | 1.79 | 0.1 | 7712 | 55 |
| nivolumab and ipilimumab macmillan | 0.69 | 0.9 | 4059 | 84 |
| nivolumab and ipilimumab colon cancer | 0.1 | 0.8 | 9519 | 12 |
| ipilimumab and nivolumab success rate | 1.21 | 0.3 | 9609 | 75 |
| nivolumab ipilimumab rcc | 0.53 | 0.7 | 3264 | 98 |
